Swiss pharma giant Roche could be among the best-placed drugmakers to tackle two of today’s biggest challenges in global ...
Biohaven Ltd. narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending.
We recently published 12 Latest Stocks on Jim Cramer’s Radar . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer ...
Thales and Universal Communication Systems Co. Ltd. (UCS) have signed a contract to equip the Royal Thai Navy’s HTMS Chakri Naruebet with an In ...
Novartis has unveiled a 10,000-square-foot radioligand therapy (RLT) production plant in Carlsbad, CA, representing a move ...
Zacks Investment Research on MSN
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have ...
In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year ...
AbbVie is ending a decade-long partnership with Calico Life Sciences, an Alphabet-funded biotech company focused on aging ...
AbbVie (ABBV) stock is in focus as the company ends its decade-long R&D deal with Calico, an Alphabet (GOOG)-backed startup ...
In a dramatic industry confrontation, pharmaceutical giant Eli Lilly is making strategic moves that could reshape market dynamics. The company announced it w ...
Generic drug giant Sandoz expects unbranded versions of Novo Nordisk's popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on ...
Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback